The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
What is the best size descriptor to use for pharmacokinetic studies in the obese?
Open accessAbstract
The prevalence of obesity in the western world is dramatically rising, with many of these individuals requiring therapeutic intervention for a variety of disease states. Despite the growing prevalence of obesity there is a paucity of information describing how doses should be adjusted, or indeed whether they need to be adjusted, in the clinical setting. This review is aimed at identifying which descriptors of body size provide the most information about the relationship between dose and concentration in the obese. The size descriptors, weight, lean body weight, ideal body weight, body surface area, body mass index, fat‐free mass, percent ideal body weight, adjusted body weight and predicted normal body weight were considered as potential size descriptors. We conducted an extensive review of the literature to identify studies that have assessed the quantitative relationship between the parameters clearance (CL) and volume of distribution (V) and these descriptors of body size. Surprisingly few studies have addressed the relationship between obesity and CL or V in a quantitative manner. Despite the lack of studies there were consistent findings: (i) most studies found total body weight to be the best descriptor of V. A further analysis of the studies that have addressed V found that total body weight or another descriptor that incorporated fat mass was the preferred descriptor for drugs that have high lipophilicity; (ii) in contrast, CL was best described by lean body mass and no apparent relationship between lipophilicity or clearance mechanism and preference for body size descriptor was found. In conclusion, no single descriptor described the influence of body size on both CL and V equally well. For drugs that are dosed chronically, and therefore CL is of primary concern, dosing for obese patients should not be based on their total weight. If a weight‐based dose individualization is required then we would suggest that chronic drug dosing in the obese subject should be based on lean body weight, at least until a more robust size descriptor becomes available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
(2000) · PubMed · Cited by 13,173
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
A formula to estimate the approximate surface area if height and weight be known. 1916.
Bois, D. D., & Bois, E. F. D. (1989) · PubMed · Cited by 5,314
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
Du BOIS, D. (1916) · Archives of Internal Medicine · doi:10.1001/archinte.1916.00080130010002 · Cited by 4,342
Simplified calculation of body surface area
(1987) · New England Journal of Medicine · doi:10.1056/nejm198710223171717 · Cited by 3,238
Indices of relative weight and obesity
Keys, A., Fidanza, F., Karvonen, M. J., Kimura, N., & Taylor, H. L. (1972) · Journal of Chronic Diseases · doi:10.1016/0021-9681(72)90027-6 · Cited by 2,055
The assessment of the amount of fat in the human body from measurements of skinfold thickness
Durnin, J. V. G. A., & Rahaman, M. M. (1967) · British Journal of Nutrition · doi:10.1079/bjn19670070 · Cited by 1,685
Nutritional and metabolic assessment of the hospitalized patient
Blackburn, G. L., Bistrian, B. R., Maini, B. S., Schlamm, H. T., & Smith, M. F. (1977) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/014860717700100101 · Cited by 1,426
Bioenergetic studies in adult patients recovering from semi-starvation.
Heymsfield, S., McManus, C., Hill, J., Digirolamo, M., Nixon, D., Head, A., & Grossman, G. (1985) · PubMed · Cited by 1,410
Validation of tetrapolar bioelectrical impedance method to assess human body composition
Lukaski, H. C., Bolonchuk, W. W., Hall, C. B., & Siders, W. A. (1986) · Journal of Applied Physiology · doi:10.1152/jappl.1986.60.4.1327 · Cited by 1,370
Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-validation study
Segal, K., Van Loan, M., Fitzgerald, P., Hodgdon, A., & Van Itallie, T. (1988) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/47.1.7 · Cited by 881
Report of the committee on the genetic constitution of autosomes other than chromosomes 1, 2, and 6
Ruddle, F. H., & Meera Khan, P. (1976) · Cytogenetic and Genome Research · doi:10.1159/000130554 · Cited by 845
Effects of Obesity on Pharmacokinetics: Implications for Drug Therapy
Cheymol, G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039030-00004 · Cited by 631
Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects
Mandema, J. W., Verotta, D., & Sheiner, L. B. (1992) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061469 · Cited by 500
Indices of relative weight and obesity
Keys, A., Fidanza, F., Karvonen, M. J., Kimura, N., & Taylor, H. L. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyu058 · Cited by 425
Relationship between total body water and surface area in normal and obese subjects
Hume, R., & Weyers, E. (1971) · Journal of Clinical Pathology · doi:10.1136/jcp.24.3.234 · Cited by 377
Clinical Pharmacy: Case Studies: Case Number 25 Gentamicin Therapy
McCarron, M. M., & Devine, B. J. (1974) · Drug Intelligence & Clinical Pharmacy · doi:10.1177/106002807400801104 · Cited by 342
Obesity and Disease Management: Effects of Weight Loss on Comorbid Conditions
Anderson, J. W., & Konz, E. C. (2001) · Obesity Research · doi:10.1038/oby.2001.138 · Cited by 330
Lean Body Mass as a Predictor of Drug Dosage: Implications for Drug Therapy
Morgan, D. J., & Bray, K. M. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426040-00005 · Cited by 299
Assessment of Actual Significance Levels for Covariate Effects in NONMEM
Wählby, U., Jonsson, E. N., & Karlsson, M. O. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1011527125570 · Cited by 292
Effect of obesity on bioelectrical impedance
Gray, D. S., Bray, G. A., Gemayel, N., & Kaplan, K. (1989) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/50.2.255 · Cited by 291
Rathbun, E. N., & Pace, N. (1945) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)51343-6 · Cited by 241
Vancomycin pharmacokinetics in normal and morbidly obese subjects
Blouin, R. A., Bauer, L. A., Miller, D. D., Record, K. E., & Griffen, W. O. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.21.4.575 · Cited by 233
Wählby, U., Jonsson, E. N., & Karlsson, M. O. (2002) · AAPS PharmSci · doi:10.1208/ps040427 · Cited by 222
Doxorubicin clearance in the obese.
Rodvold, K. A., Rushing, D. A., & Tewksbury, D. A. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.8.1321 · Cited by 213
Pharmacokinetic Considerations in Obesity
Blouin, R. A., & Warren, G. W. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js980173a · Cited by 202
The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers
Sanderink, G., Le Liboux, A., Jariwala, N., Harding, N., Ozoux, M., Shukla, U., Montay, G., Boutouyrie, B., & Miro, A. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127114 · Cited by 186
Clinical Pharmacokinetics of Drugs in Obesity: An Update
Cheymol, G. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199325020-00003 · Cited by 184
The relation of total body potassium to height, weight, and age in normal adults
Boddy, K., King, P. C., Hume, R., & Weyers, E. (1972) · Journal of Clinical Pathology · doi:10.1136/jcp.25.6.512 · Cited by 176
Vancomycin dosing in morbidly obese patients
Bauer, L. A., Black, D. J., & Lill, J. S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050524 · Cited by 162
James, W. P. T. (1977) · Nutrition Bulletin · doi:10.1111/j.1467-3010.1977.tb00966.x · Cited by 129
Vance‐Bryan, K., Guay, D. R. P., Gilliland, S. S., Rodvold, K. A., & Rotschafer, J. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.436 · Cited by 114
The Impact of Obesity and Disease on Busulfan Oral Clearance in Adults
Gibbs, J. P., Gooley, T. A., Corneau, B., Murray, G., STEWART, P. S., Appelbaum, F. R., & Slattery, J. T. (1999) · Blood · doi:10.1182/blood.v93.12.4436 · Cited by 111
A Standard Weight Descriptor for Dose Adjustment in the Obese Patient
Duffull, S. B., Dooley, M. J., Green, B., Poole, S. G., & Kirkpatrick, C. M. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443150-00007 · Cited by 111
Self-citationThe Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam
Abernethy, D. R., Greenblatt, D. J., Divoll, M., Smith, R. B., & Shader, R. I. (1984) · Clinical Pharmacokinetics · doi:10.2165/00003088-198409020-00005 · Cited by 99
Glomerular filtration rate in severely overweight normotensive humans
Anastasio, P., Spitali, L., Frangiosa, A., Molino, D., Stellato, D., Cirillo, E., Pollastro, R. M., Capodicasa, L., Sepe, J. J., Federico, P., et al. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70052-7 · Cited by 90
Obesity, Body Fat Distribution, and Ambulatory Blood Pressure in Children and Adolescents
Lurbe, E., Álvarez, V., & Redón, J. (2001) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2001.00492.x · Cited by 84
Phenytoin Disposition in Obesity: Determination of Loading Dose
Abernethy, D. R., & Greenblatt, D. J. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060050066010 · Cited by 79
Womersley, J., Boddy, K., King, P. C., & Durnin, J. V. G. A. (1972) · Clinical Science · doi:10.1042/cs0430469 · Cited by 77
Kowalski, K. G., & Hutmacher, M. M. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1011579109640 · Cited by 71
A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.
Bowman, S. L., Hudson, S., Simpson, G., Munro, J., & Clements, J. (1986) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1986.tb02837.x · Cited by 68
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution
Lind, M., Margison, J. M., Cerny, T., Thatcher, N., & Wilkinson, P. M. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00692355 · Cited by 66
Lithium pharmacokinetics in the obese
Reiss, R. A., Haas, C. E., Karki, S. D., Gumbiner, B. M., Welle, S. L., & Carson, S. W. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.47 · Cited by 64
Bénézet, S., Guimbaud, R., Chatelut, É., Chevreau, C., Bugat, R., & Canal, P. (1997) · Annals of Oncology · doi:10.1023/a:1008259009500 · Cited by 57
Nguyen, L., Tranchand, B., Puozzo, C., & Variol, P. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01581.x · Cited by 56
Renal Hemodynamics in Recent-Onset Type II Diabetes
Nowack, R., Raum, E., Blum, W. F., & Ritz, E. (1992) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70296-2 · Cited by 56
Prolongation of Drug Half-Life due to Obesity: Studies of Desmethyldiazepam (Clorazepate)
Abernethy, D. R., Greenblatt, D. J., Divoll, M., & Shader, R. I. (1982) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600710827 · Cited by 55
The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.
CHEYMOL, G., WEISSENBURGER, J., Poirier, J., & Gellee, C. (1995) · PubMed · Cited by 52
Procainamide Disposition in Obesity
Christoff, P. B., Conti, D. R., Naylor, C. W., & Jusko, W. J. (1983) · Annals of Pharmacotherapy · doi:10.1177/106002808301700704 · Cited by 44
Caffeine pharmacokinetics in obesity and following significant weight reduction.
Caraco, Y., Zylber‐Katz, E., Em, B., & Lévy, M. (1995) · PubMed · Cited by 44
Carbamazepine Phakmacokinetics in Obese and Lean Subjects
Caraco, Y., Zylber, E. A., Berry, E. M., & Levy, M. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502900902 · Cited by 41
Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers
Jeunne, C. L., Poirier, J., CHEYMOL, G., Ertzbischoff, O., Engel, F., & Hugues, F. C. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00265912 · Cited by 26
The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics
Jaber, L. A., Antal, E. J., Slaughter, R. L., & Welshman, I. R. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315518 · Cited by 26
Erroneous Nomograms for Body-Surface Area
Turcotte, G. (1979) · New England Journal of Medicine · doi:10.1056/nejm197906073002320 · Cited by 16
Cited by
Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics
Anderson, B. J., & Holford, N. H. G. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094708 · Cited by 1,125
Quantification of Lean Bodyweight
Janmahasatian, S., Duffull, S. B., Ash, S., Ward, L. C., Byrne, N. M., & Green, B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00004 · Cited by 900
Self-citationFalagas, M. E., & Kompoti, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70523-0 · Cited by 811
Clinical pharmacokinetics and pharmacodynamics of propofol
Sahinovic, M. M., Struys, M. M. R. F., & Absalom, A. R. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0672-3 · Cited by 809
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
Hanley, M. J., Abernethy, D. R., & Greenblatt, D. J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318100-000000000-00000 · Cited by 773
Metadata
- Authors
- Green, B., & Duffull, S. B.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2004-06-25
- Volume
- 58
- Issue
- 2
- Pages
- 119-133
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2078501925
- Cited by
- 353
- References
- 58
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.